NEW Q2. Mark Johnson is controller for a Pharmaceutical company. During the company's midyear review, Johnson notes that the company's R&D expenditures are already $3.0 billion, ņearly 40% above the midyear target. In a meeting with the CFO later that day, Johnsons delivers the bad news to the CFO, Pauline Stewart. Stewart was shocked and outraged that the R&D spending had gotten out of control. Stewart wasn't any more understanding when Johnson revealed that the excess cost was entirely related to research and development of a new drug, Lucexx, which was expected to go to market next year. The new drug would result in large profits for the company, if the product could be approved
Cost-Volume-Profit Analysis
Cost Volume Profit (CVP) analysis is a cost accounting method that analyses the effect of fluctuating cost and volume on the operating profit. Also known as break-even analysis, CVP determines the break-even point for varying volumes of sales and cost structures. This information helps the managers make economic decisions on a short-term basis. CVP analysis is based on many assumptions. Sales price, variable costs, and fixed costs per unit are assumed to be constant. The analysis also assumes that all units produced are sold and costs get impacted due to changes in activities. All costs incurred by the company like administrative, manufacturing, and selling costs are identified as either fixed or variable.
Marginal Costing
Marginal cost is defined as the change in the total cost which takes place when one additional unit of a product is manufactured. The marginal cost is influenced only by the variations which generally occur in the variable costs because the fixed costs remain the same irrespective of the output produced. The concept of marginal cost is used for product pricing when the customers want the lowest possible price for a certain number of orders. There is no accounting entry for marginal cost and it is only used by the management for taking effective decisions.
![NEW
Q2. Mark Johnson is controller for a Pharmaceutical company. During the
company's midyear review, Johnson notes that the company's R&D
expenditures are already $3.0 billion, nearly 40% above the midyear
target. In a meeting with the CFO later that day, Johnsons delivers the
bad news to the CFO, Pauline Stewart. Stewart was shocked and
outraged that the R&D spending had gotten out of control. Stewart wasn't
any more understanding when Johnson revealed that the excess cost
was entirely related to research and development of a new drug, Lucexx,
which was expected to go to market next year. The new drug would
result in large profits for the company, if the product could be approved
by year-end. Johnson came up with the following ideas for making the
third-quarter budgeted targets:Sell off rights to the drug, Martek. The
company had not planned on doing this because, under current market
conditions, it would get less than fair value. It would, however, result in a
onetime revenue that could offset the budget shortfall. The patent on
Martek is about to expire, after which any competitor can make the drug.
On balance, the results on the company of this action are:
A.An overall positive effect on short-term profits, while not affecting expected long-term profits
B.An overall negative effect on short-term profits, while not affecting expected long-term profits
OC.An overall positive effect on short-term profits, while diminishing expected long-term profits
D.No predictable effect on short-term profits](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2Ffa5ff83c-bb91-4cdb-982b-77d31ade486d%2Fe0c8e17e-65a2-44ed-94ec-99873c97ab0d%2F73yp0un_processed.jpeg&w=3840&q=75)
![](/static/compass_v2/shared-icons/check-mark.png)
Trending now
This is a popular solution!
Step by step
Solved in 2 steps
![Blurred answer](/static/compass_v2/solution-images/blurred-answer.jpg)
![FINANCIAL ACCOUNTING](https://compass-isbn-assets.s3.amazonaws.com/isbn_cover_images/9781259964947/9781259964947_smallCoverImage.jpg)
![Accounting](https://www.bartleby.com/isbn_cover_images/9781337272094/9781337272094_smallCoverImage.gif)
![Accounting Information Systems](https://www.bartleby.com/isbn_cover_images/9781337619202/9781337619202_smallCoverImage.gif)
![FINANCIAL ACCOUNTING](https://compass-isbn-assets.s3.amazonaws.com/isbn_cover_images/9781259964947/9781259964947_smallCoverImage.jpg)
![Accounting](https://www.bartleby.com/isbn_cover_images/9781337272094/9781337272094_smallCoverImage.gif)
![Accounting Information Systems](https://www.bartleby.com/isbn_cover_images/9781337619202/9781337619202_smallCoverImage.gif)
![Horngren's Cost Accounting: A Managerial Emphasis…](https://www.bartleby.com/isbn_cover_images/9780134475585/9780134475585_smallCoverImage.gif)
![Intermediate Accounting](https://www.bartleby.com/isbn_cover_images/9781259722660/9781259722660_smallCoverImage.gif)
![Financial and Managerial Accounting](https://www.bartleby.com/isbn_cover_images/9781259726705/9781259726705_smallCoverImage.gif)